# Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

> **NCT01051193** · PHASE2,PHASE3 · COMPLETED · sponsor: **Nobelpharma** · enrollment: 88 (actual)

## Conditions studied

- Partial Onset Seizures

## Interventions

- **DRUG:** Oxcarbazepine

## Key facts

- **NCT ID:** NCT01051193
- **Lead sponsor:** Nobelpharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-05
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051193, "Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01051193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*